Semaglutide and Sudden Vision Loss (NAION): What Men Should Know

The "Ozempic blindness" risk is real but rare. European and UK regulators now list NAION, a stroke of the optic nerve, as a "very rare" side effect of semaglutide, affecting up to 1 in 10,000 people. As of October 2026, the US labels on DailyMed do not list it. The men who should pay closest attention are the ones who already carry NAION risk factors: sleep apnea, diabetes, high blood pressure, age over 50 and a "crowded" optic disc.

What NAION is

Nonarteritic anterior ischemic optic neuropathy is a loss of blood flow to the front of the optic nerve, where it leaves the eye. The Merck Manual describes it as an infarction of the optic disc that usually affects people around 50 or older. The vision loss is painless and develops over minutes to days, and some patients first notice it when they wake up.

The outlook is sobering. Merck says there is no established treatment, although up to 40% of patients get some mild spontaneous improvement. About 15% develop NAION in the other eye within five years. The American Academy of Ophthalmology's patient page states that vision loss from ischemic optic neuropathy "is usually permanent."

Where the semaglutide signal came from

The 2024 Mass Eye and Ear study

The concern went public in July 2024 with a JAMA Ophthalmology study by Hathaway and colleagues. Researchers reviewed records of 16,827 patients at one academic eye institution and compared people prescribed semaglutide with matched patients on other drugs. Semaglutide was associated with a higher NAION risk in patients with type 2 diabetes (hazard ratio 4.28) and in patients with overweight or obesity (hazard ratio 7.64).

The authors were careful: their findings "suggest an association," and because the study was observational, they said causation needed further study. Patients at a specialty eye center are not a typical population, so the size of those ratios was always likely to shrink in broader data.

The 2026 VA study

Larger studies since then have mostly found a smaller but real signal. In February 2026, JAMA Ophthalmology published a study of US veterans with type 2 diabetes on metformin (Heberer et al., JAMA Ophthalmol 2026), summarized by Optometry Times. It compared 11,478 people who started semaglutide with 90,883 who started an SGLT2 inhibitor.

Source: Heberer et al., JAMA Ophthalmology 2026;144(3):259-264, figures as reported by Optometry Times.

The authors described the risk as rare and advised clinicians to counsel patients and encourage prompt evaluation of visual symptoms. Put plainly, the unadjusted rates differ by about 56 cases per 100,000 person-years, roughly 1 extra NAION case per 1,800 people treated for a year in this group, which is uncommon but not negligible for a diabetic population that already has elevated baseline risk.

What regulators have concluded

Europe: "very rare"

In June 2025, the European Medicines Agency's safety committee (PRAC) concluded that NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people. It recommended adding NAION to the product information for Ozempic, Rybelsus and Wegovy. Patients with sudden vision loss or rapidly worsening eyesight should contact their doctor without delay, and semaglutide should be stopped if NAION is confirmed.

United Kingdom: urgent referral

The UK's MHRA Drug Safety Update of February 5, 2026 followed suit. It cites the EMA estimate of about a two-fold increase in relative risk in adults with type 2 diabetes, or roughly one extra case per 10,000 treated per year. The MHRA had received three UK reports suggestive of NAION through August 2025, against about 10.2 million semaglutide packs dispensed over five years. It tells clinicians to refer patients with sudden vision loss urgently to an ophthalmologist, and to ask specifically about semaglutide because privately prescribed supplies may not show up in medical records.

United States: not on the label yet

As of October 2026, the US prescribing information on DailyMed for Ozempic injection (revised May 2026), Wegovy (revised June 2026) and Rybelsus and Ozempic tablets (revised January 2026) does not list NAION in its warnings or its postmarketing adverse reactions. None of the postmarketing sections has an eye-disorders entry.

What the US labels do carry is a separate warning about diabetic retinopathy complications. The Ozempic label notes that rapid improvement in blood sugar "has been associated with a temporary worsening of diabetic retinopathy" and that patients with a history of retinopathy should be monitored. That is a different eye problem from NAION, but it is one more reason men with diabetes should keep regular eye exams.

The absence from the US label doesn't mean the risk doesn't exist; it means the FDA had not added it as of these revisions. Labels change, so check DailyMed for the current version.

Why this matters more for men

NAION's known risk factors overlap heavily with the reasons men get prescribed a GLP-1 in the first place. The table shows where each one comes from.

Sources: Merck Manual Professional, American Academy of Ophthalmology, Viagra prescribing information.

Sleep apnea

Both the Merck Manual and AAO list obstructive sleep apnea as a risk factor. Merck notes that NAION is often first noticed on waking, which has led researchers to suspect low blood pressure during the night. Many men on GLP-1s have sleep apnea, and some are on tirzepatide specifically for it. The EMA review covered semaglutide only; the MHRA says it did not include other GLP-1 drugs and that the MHRA is reviewing evidence for them. Treating your apnea is worthwhile on its own, and it's one of the few NAION risk factors you can act on.

Viagra and Cialis

This is a specifically male overlap. The Viagra label carries an NAION warning in its Warnings and Precautions section. It reports a background rate of 2.5 to 11.8 cases per 100,000 men aged 50 and older each year, and cites studies showing roughly double the risk shortly after PDE5 inhibitor use, while stating the data don't prove causation. It tells patients to stop all PDE5 inhibitors and seek care if they suddenly lose vision. No US label addresses the combination of a PDE5 inhibitor and semaglutide, so if you take both, make sure each prescriber knows about the other drug.

Diabetes and blood pressure

The MHRA cites background NAION rates of 11.4 to 82 per 100,000 person-years in people with type 2 diabetes, higher than the general population over 40. A man with diabetes, hypertension and apnea is starting from a higher baseline, so a doubling of a higher number matters more for him than for a healthy 35-year-old.

Symptoms that need same-day eye care

Speed matters even though NAION has no proven treatment, because sudden vision loss has other causes that do. Merck notes that giant cell arteritis, an inflammatory artery disease that can blind the other eye if steroids are delayed, "should always be ruled out" with blood tests. Tell the doctor you take semaglutide or tirzepatide, and any erectile dysfunction drug.

What to tell your prescriber before you start

1. Any past NAION, optic nerve problem or unexplained vision loss in either eye.
2. Whether an eye doctor has ever told you that you have a small or "crowded" optic disc.
3. Your sleep apnea diagnosis and whether you're using treatment consistently.
4. Diabetes, especially any diabetic retinopathy, and your last dilated eye exam.
5. Viagra, Cialis or other PDE5 inhibitor use, and amiodarone, which Merck also lists.

Then ask: given my history, do the benefits outweigh this risk for me, and should I see an eye doctor for a baseline exam first? For many men, the cardiovascular, kidney and weight benefits will still win out. That's a judgment to make with the facts in hand.

Where this guide stops

This article reflects regulator statements and DailyMed labels as of October 2026. Observational studies can't prove semaglutide causes NAION, and the risk estimates may change as more data come in. Nothing here is a reason to stop a prescribed medicine on your own; talk to your prescriber first. Compounded semaglutide is not FDA-approved and has no label data of its own.

Sources

1. Merck Manual Professional: Ischemic Optic Neuropathy
2. American Academy of Ophthalmology: What Is Ischemic Optic Neuropathy?
3. Hathaway et al. Risk of NAION in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024 (PubMed)
4. Heberer K et al. New-Onset NAION and Initiators of Semaglutide in US Veterans With Type 2 Diabetes. JAMA Ophthalmol 2026;144(3):259-264 (PubMed)
5. Optometry Times: Study confirms NAION as rare, severe side effect of initiating GLP-1 treatment for T2D (Feb 2026)
6. EMA: PRAC meeting highlights, 2-5 June 2025
7. MHRA Drug Safety Update: Semaglutide and risk of NAION (Feb 2026)
8. DailyMed: Ozempic (semaglutide) injection prescribing information
9. DailyMed: Wegovy (semaglutide) prescribing information
10. DailyMed: Rybelsus and Ozempic (oral semaglutide) tablets prescribing information
11. DailyMed: Viagra (sildenafil) prescribing information

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.